Arcutis Biotherapeutics, Inc.
ARQT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 0.03 | -0.07 | -0.51 |
| FCF Yield | -6.66% | -110.56% | -34.50% | -17.14% |
| EV / EBITDA | -15.73 | -1.50 | -3.27 | -4.89 |
| Quality | ||||
| ROIC | -48.01% | -82.59% | -73.07% | -54.97% |
| Gross Margin | 90.27% | 91.63% | 79.54% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.94 | 0.83 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 276.39% | – | – | – |
| Free Cash Flow Growth | 54.62% | 11.93% | -60.00% | -54.93% |
| Safety | ||||
| Net Debt / EBITDA | -0.36 | -0.52 | -0.51 | 0.09 |
| Interest Coverage | -4.73 | -8.11 | -19.27 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.32 | 0.38 | 0.10 | 0.65 |
| Cash Conversion Cycle | 141.53 | 241.61 | 201.94 | -2,953.01 |